HER2

You have access
Differences of HER2 Status by HercepTest and PATHWAY 4B5 Immunohistochemical Assays in Breast Cancer
SHINSUKE SASADA, MOMOKO TAKAYA, KANAKO SUZUKI, MUTSUMI FUJIMOTO, HARUKA IKEJIRI, AI AMIOKA, HIDEO SHIGEMATSU, KOJI ARIHIRO and MORIHITO OKADA

Anticancer Research February 2026, 46 (2) 1123-1130; DOI: https://doi.org/10.21873/anticanres.18015
Open Access
Exposure to Hypoxic Conditions Up-regulates HER2 in Breast Cancer Cell Lines
NOBUYASU SUGANUMA, NAO SAITO, MIO YASUKAWA, TAKASHI YAMANAKA, TOSHINARI YAMASHITA, YOHEI MIYAGI, AYA SAITO and DAISUKE HOSHINO

Anticancer Research December 2024, 44 (12) 5187-5192; DOI: https://doi.org/10.21873/anticanres.17344
Open Access
Effects of Extended Fixation on Advanced Gastric Cancer HER2 Status Assessment Using IHC and FISH
JUNYA KONDO, SHIGEFUMI YOSHINO, MICHIHISA IIDA, SHIGERU TAKEDA, CHIYO NAKASHIMA, YUSAKU WATANABE, MITSUO NISHIYAMA, YUKIO TOKUMITSU, YOSHITARO SHINDO, TAKU NISHIMURA, NOBUAKI SUZUKI, YOSHINOBU HOSHII, HIROSHI ITOH and HIROAKI NAGANO

Anticancer Research February 2024, 44 (2) 621-630; DOI: https://doi.org/10.21873/anticanres.16851
You have access
Immunohistochemical Analysis of HER2, EGFR, and Nectin-4 Expression in Upper Urinary Tract Urothelial Carcinoma
MAMORU HASHIMOTO, KAZUTOSHI FUJITA, EISUKE TOMIYAMA, SAIZO FUJIMOTO, SHOGO ADOMI, ERI BANNO, TAKAFUMI MINAMI, TETSUYA TAKAO, MASAHIRO NOZAWA, HIROAKI FUSHIMI, KAZUHIRO YOSHIMURA, NORIO NONOMURA and HIROTSUGU UEMURA

Anticancer Research January 2023, 43 (1) 167-174; DOI: https://doi.org/10.21873/anticanres.16146
You have access
Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer
GEORGIOS RIGAKOS, EVANGELIA RAZIS, GEORGIA-ANGELIKI KOLIOU, GEORGIOS OIKONOMOPOULOS, ELEFTHERIA TSOLAKI, JEFF SPERINDE, SOFIA CHRISAFI, GEORGE ZARKAVELIS, ELISSAVET PAZARLI, ANNA BATISTATOU, HELEN P. KOUREA, PAVLOS PAPAKOSTAS, DIMITRIOS BAFALOUKOS, NATALIA I. ASIMAKOPOULOU, ELENI RES, ATHANASIOS KOTSAKIS, DIMITRIOS PECTASIDES, ANGELOS KOUTRAS, CHRISTOS CHRISTODOULOU and GEORGE FOUNTZILAS

Anticancer Research April 2021, 41 (4) 1793-1802; DOI: https://doi.org/10.21873/anticanres.14945
You have access
Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice
MASAHIRO OKAMOTO, WAKAKO TAJIRI, HIROKI UEO, TAKANOBU MASUDA, HIDEKI IJICHI, CHINAMI KOGA, YOSHIAKI NAKAMURA, KENICHI TAGUCHI, SHINJI OHNO and ERIKO TOKUNAGA

Anticancer Research June 2020, 40 (6) 3315-3323; DOI: https://doi.org/10.21873/anticanres.14314
You have access
Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma
MASASHI TAKAHASHI, KAZUMASA FUKUDA, YOSHIRO SAIKAWA, RIEKO NAKAMURA, NORIHITO WADA, HIROFUMI KAWAKUBO, HIROYA TAKEUCHI and YUKO KITAGAWA

Anticancer Research April 2020, 40 (4) 1921-1930; DOI: https://doi.org/10.21873/anticanres.14147
You have access
Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma
RUTH BAUMGARTNER, HOSSEIN TAGHIZADEH, GERD JOMRICH, SEBASTIAN FRIEDRICH SCHOPPMANN, MATTHIAS PREUSSER and AYSEGUL ILHAN-MUTLU

Anticancer Research February 2020, 40 (2) 965-975; DOI: https://doi.org/10.21873/anticanres.14030
You have access
Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer
TAKASHI KIJIMA, TAKAAKI ARIGAMI, YOSHIKAZU UENOSONO, TSUBASA HIRAKI, SHIGEHIRO YANAGITA, DAISUKE MATSUSHITA, KEISHI OKUBO, MASATAKA SHIMONOSONO, SUMIYA ISHIGAMI, KOSEI MAEMURA, AKIHIDE TANIMOTO and SHOJI NATSUGOE

Anticancer Research January 2020, 40 (1) 75-80; DOI: https://doi.org/10.21873/anticanres.13927
You have access
Efficacy of Afatinib and Lapatinib Against HER2 Gene-amplified Trastuzumab-sensitive and -resistant Human Gastric Cancer Cells
SUSUMU NAKATA, MITSUGU FUJITA and HAYAO NAKANISHI

Anticancer Research November 2019, 39 (11) 5927-5932; DOI: https://doi.org/10.21873/anticanres.13797

Main menu

User menu

Search

HER2

Pages